New drug combo aims to wipe out lingering leukemia cells
NCT ID NCT07264010
First seen Jan 11, 2026 · Last updated Apr 11, 2026 · Updated 16 times
Summary
This study is testing whether a combination of two existing drugs, sorafenib and venetoclax, can help patients with acute myeloid leukemia (AML) who still have very small amounts of cancer left after their first treatment. The goal is to see if this 'pre-emptive' therapy can reduce or eliminate these remaining cancer cells to prevent the disease from coming back. The trial will enroll 87 patients at multiple hospitals to measure how well the treatment works and monitor its safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKAEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.